G1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasted to Post FY2026 Earnings of $0.72 Per Share

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for G1 Therapeutics in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst E. White now forecasts that the company will post earnings of $0.72 per share for the year, down from their previous forecast of $0.76. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.64) per share.

Other analysts have also issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th.

G1 Therapeutics Price Performance

Shares of GTHX opened at $4.49 on Friday. The company has a 50 day moving average of $3.94 and a two-hundred day moving average of $3.09. The company has a quick ratio of 3.45, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The company has a market cap of $234.74 million, a price-to-earnings ratio of -7.24 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $14.48 million during the quarter, compared to analysts’ expectations of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same period in the previous year, the firm earned ($0.53) EPS.

Insiders Place Their Bets

In other news, insider Rajesh Malik sold 28,600 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the sale, the insider now directly owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.23% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. FinTrust Capital Advisors LLC increased its holdings in G1 Therapeutics by 154,946.2% in the 4th quarter. FinTrust Capital Advisors LLC now owns 100,780 shares of the company’s stock worth $307,000 after buying an additional 100,715 shares during the period. Capstone Investment Advisors LLC purchased a new stake in shares of G1 Therapeutics in the 4th quarter valued at $76,000. Financial Advocates Investment Management acquired a new stake in shares of G1 Therapeutics in the fourth quarter worth $39,000. Jump Financial LLC purchased a new position in shares of G1 Therapeutics during the fourth quarter worth $105,000. Finally, Choreo LLC acquired a new position in G1 Therapeutics during the fourth quarter valued at $107,000. 24.21% of the stock is currently owned by hedge funds and other institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.